Dashboard
Manage Tickers

CUE Cue Biopharma, Inc.

Nasdaq cuebiopharma.com


$ 0.62 $ 0.00 (0 %)    

Wednesday, 19-Nov-2025 04:08:14 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 599.61 $ 0.00 (0 %)
DIA $ 462.23 $ 0.00 (0 %)
SPY $ 663.12 $ 0.00 (0 %)
TLT $ 88.97 $ 0.00 (0 %)
GLD $ 378.09 $ 0.00 (0 %)
$ 0.58
$ 0.58
$ 0.55 x 1
$ 0.74 x 400
-- - --
$ 0.54 - $ 1.75
95,217
na
45.67M
$ 1.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-21-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-16-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-09-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-14-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-14-2018 03-31-2018 10-Q
32 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immunoscape-announces-exclusive-in-licensing-deal-with-cue-biopharma-to-lead-development-of-distinct-therapies-to-attack-solid-tumor-cancers
ImmunoScape Announces Exclusive In-Licensi...
11/13/2025 18:14:35

"Seed-and-Boost" Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy LandscapeImmunoScap...

cue-biopharma-q3-eps-007-beats-009-estimate-sales-2149m-miss-2290m-estimate
Cue Biopharma Q3 EPS $(0.07) Beats $(0.09)...
11/12/2025 21:32:43

cue-biopharma-and-immunoscape-announce-exclusive-collaboration-and-license-agreement-immunoscape-to-cevelop-a-seed-and-boost-immunotherapy-combining-cue-biopharmas-cue-100-with--immunoscapes-tcrs
Cue Biopharma And ImmunoScape Announce Exc...
11/06/2025 13:02:39

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
11/03/2025 12:05:47

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/09/2025 21:06:16

lucid-capital-markets-initiates-coverage-on-cue-biopharma-with-buy-rating-announces-price-target-of-4
LUCID CAPITAL MARKETS Initiates Coverage O...
08/25/2025 17:27:53

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces P...

cue-biopharma-initiates-investigator-sponsored-trial-of-cue-102-for-recurrent-glioblastoma-multiforme
Cue Biopharma Initiates Investigator Spons...
08/13/2025 12:09:02

cue-biopharma-q2-eps-009-beats-014-estimate-sales-2954m-beat-2396m-estimate
Cue Biopharma Q2 EPS $(0.09) Beats $(0.14)...
08/12/2025 20:33:23

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 21:06:00

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 17:06:26

reported-earlier-cue-biopharma-reports-50-overall-response-rate-and-88-12-month-survival-in-cue-101-trial-for-hpv-cancers
Reported Earlier: Cue Biopharma Reports 50...
07/16/2025 16:06:52

Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patie...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 21:05:47

cue-biopharma-issues-update-on-its-clinical-stage-asset-cue-101-representative-of-cue-100-series-data-highlights-include-orr-of-50-in-treatment-naive-patients-with-hpv-rm-hnscc
Cue Biopharma Issues Update On Its Clinica...
07/01/2025 20:08:30

ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 monthsBOSTON, July 01...

cue-biopharma-receives-fda-pre-ind-feedback-for-lead-autoimmune-therapy-cue-401-plans-ind-filing-pending-final-studies
Cue Biopharma Receives FDA Pre-IND Feedbac...
06/24/2025 20:50:01

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...

cue-biopharma-ceo-daniel-passeri-to-serve-as-interim-cfo-kerri-ann-millar-resigns-as-cfo
Cue Biopharma CEO Daniel Passeri To Serve ...
06/10/2025 20:05:08

 - SEC Filing

cue-biopharma-q1-eps-017-misses-015-estimate-sales-42100k-miss-127m-estimate
Cue Biopharma Q1 EPS $(0.17) Misses $(0.15...
05/12/2025 20:49:12

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/15/2025 21:05:49

reported-earlier-cue-biopharma-prices-20m-public-offering-of-common-stock-and-warrants-at-079
Reported Earlier, Cue Biopharma Prices $20...
04/15/2025 06:31:04

cue-biopharma-announces-proposed-public-offering-no-size-or-amount-disclosed
Cue Biopharma Announces Proposed Public Of...
04/14/2025 21:06:35

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...

cue-biopharma-and-boehringer-ingelheim-announce-strategic-partnership-to-develop-and-commercialize-first-in-class-bispecific-t-cell-engaging-b-cell-depletion-therapy-cue-501-for-autoimmune-and-inflammatory-diseases-aiming-for-earlier-intervention-and-long-term-disease-control
Cue Biopharma And Boehringer Ingelheim Ann...
04/14/2025 21:03:20

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unm...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION